NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for EKR Therapeutics Inc


Results 1 - 7


Refine Search
Display Mode: Context | Summary
Drugs from Biogen Idec and Merck are the Most Promising Therapies in Development in the Acute Heart Failure Market
2009 FEB 16 ... Acute Heart Failure finds that the launch of Adentri and rolofylline, along with EKR Therapeutics' ularitide, will be the primary drivers of growth in the acute heart ... be well received by physicians and patients." Keywords: Biogen Idec Inc., Biotechnology Business, Biotechnology Company, Cardiology, Drugs, Heart Failure, Merck ...
Subject: Heart Failure
Price: $3.00
*
EKR Therapeutics Announces Richard DeSimone Named CFO of the Year by the New Jersey Technology Council
2009 JUN 29 ... Investment, Marketing, Technology, Venture CapitalPharmaceuticals, Therapy, Treatment, EKR Therapeutics Inc. This article was prepared by Biotech Business Week editors from staff ...
Subject: EKR Therapeutics Inc.
Price: $3.00
*
EKR Therapeutics Announces the Appointment of Dave Iwanicki as Senior Vice President of Corporate Development
2009 AUG 10 ... Advertising, Biopharmaceuticals, Drugs, Pharmaceuticals, Therapies, Therapy, Treatment, EKR Therapeutics Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: EKR Therapeutics, Inc.
Price: $3.00
*
EKR Therapeutics Receives Notice of Patent Allowance for Ready-to-Use Cardene(R) I.V. Bags, a Specialty Product Line for Treating Acute Hypertension in Emergency and Critical-Care Settings
2009 NOV 9 ... Actions, Therapy, Treatment, U.S. Food and Drug Administration, Vasodilator Agent, EKR Therapeutics Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: EKR Therapeutics, Inc.
Price: $3.00
*
EKR Therapeutics to Present at the 2009 UBS Global Life Sciences Conference
2009 SEP 28 ... Medical Devices, Oncology, Pharma, Critical Care, Pharmaceuticals, Therapy, Treatment, EKR Therapeutics Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: EKR Therapeutics, Inc.
Price: $3.00
*
Howard Weisman, Chairman & CEO of EKR Therapeutics, Named Ernst & Young Entrepreneur of the Year® 2009 Award Winner for the New Jersey Pharmaceutical Industry
2009 JUL 6 ... Private Equity, Technology, Venture CapitalPharmaceuticals, Therapy, Treatment, EKR Therapeutics Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: EKR Therapeutics, Inc.
Price: $3.00
*
John E. Bailye, Dendrite Founder, Joins EKR Therapeutics as Executive Chairman; Expansion in Board Signifies Key Growth Milestone
2009 SEP 21 ... Pharmaceutical, Other Health, Critical Care, Pharmaceuticals, Therapy, Treatment, EKR Therapeutics Inc. This article was prepared by Biotech Business Week editors from staff and ...
Subject: EKR Therapeutics, Inc.
Price: $3.00
*

Results 1 - 7




-----------------------
PR Login